Would you consider immunotherapy in high-risk resectable MSI-H colorectal cancer?

Immunotherapy demonstrated great activity in treating metastatic MSI-H colorectal cancer (CheckMate 142 study, KEYNOTE-177 study, etc). There are now several small studies showing the activity of immunotherapy in early stage or locally advanced colorectal cancer.

The NICHE study enrolled 40 patients...